Xyall
A medtech innovator in molecular pathology
Xyall has raised €14M across 2 funding rounds from 7 investors, most recently a round in Feb 2026. Based in Eindhoven, Netherlands; active in Healthtech. Data as of 28 Oct 2026.
Eindhoven, Netherlandsxyall.com ↗
Total raised
€14M
€13,600,000
Funding rounds
2
Investors
7
distinct backers
Active since
2022-05
latest 2026-02
Funding by year
EUR raised per year · 2026 YTDXyall — funding by year — interactive chart.
Data table
| Xyall — funding by year | |
|---|---|
| 2022 | €6.0M |
| 2026 | €7.6M |
Signals
High confidenceRaise-next likelihood38
base rate 30% for Other
- ▲ In typical raise window
- ▲ Up-round momentum
Exit likelihood17
base rate 11% (2+ rounds)
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-02-17 | Other | €7.6M | Brabant Development Agency (BOM),Capricorn Healthtech Fund II,Capricorn Partners,Health Investment Partners (HIP),Private Investors,Sioux Technologies | View deal → |
| 2022-05-26 | Series B | €6.0M | Brabant Development Agency,Health Investment Partners (HIP),Private Investors,Sioux Technologies | View deal → |
Investors
7Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Picnic€1.7BNetherlands · E-commerce
- Just Eat Takeaway€1.6BNetherlands · Foodtech
- Nebius€1.5BNetherlands · Cloud
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData